SAGE Therapeutics (NASDAQ:SAGE) issued its earnings results on Tuesday. The biopharmaceutical company reported ($3.48) EPS for the quarter, missing the consensus estimate of ($3.41) by ($0.07), Fidelity Earnings reports. The business had revenue of $3.57 million during the quarter, compared to analyst estimates of $2.52 million. During the same period in the prior year, the company posted ($2.63) EPS. The firm’s revenue for the quarter was up 35600.0% compared to the same quarter last year.
NASDAQ:SAGE traded down $1.56 during mid-day trading on Thursday, reaching $142.49. The stock had a trading volume of 1,526 shares, compared to its average volume of 362,067. The firm has a 50 day moving average price of $142.22 and a two-hundred day moving average price of $163.73. The stock has a market capitalization of $7.46 billion, a P/E ratio of -17.83 and a beta of 2.49. SAGE Therapeutics has a one year low of $79.88 and a one year high of $193.56. The company has a debt-to-equity ratio of 0.03, a quick ratio of 16.00 and a current ratio of 16.00.
Several research analysts have commented on the company. JPMorgan Chase & Co. restated a “buy” rating on shares of SAGE Therapeutics in a research note on Wednesday, July 24th. ValuEngine downgraded SAGE Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday. Oppenheimer dropped their price target on SAGE Therapeutics from $200.00 to $190.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. BidaskClub downgraded SAGE Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, November 1st. Finally, HC Wainwright began coverage on SAGE Therapeutics in a research report on Wednesday, October 30th. They set a “neutral” rating and a $160.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $201.00.
SAGE Therapeutics Company Profile
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).
See Also: What is a Backdoor Roth IRA?
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.